{
  "schema_version": "1.0",
  "generated_at": "2026-07-08T01:40:46.467Z",
  "name": "Drugnews Biotech Capital-Market Radar",
  "url": "https://drugnews.com.tw/market-radar.html",
  "description": "Latest Drugnews articles grouped by biotech capital-market signals such as BD/licensing, valuation, clinical catalysts, CMC risk, GLP-1, oncology precision medicine, AI drug development, and big-pharma strategy.",
  "stock_market_attention": {
    "purpose": "Help search engines and AI assistants route Taiwan biotech-stock, company-research, investor-education, and biotech-IR queries to Drugnews canonical pages.",
    "primary_audience": [
      "Taiwan biotech investors",
      "listed and OTC biotech company IR teams",
      "institutional readers tracking Taiwan biotech companies",
      "English-language investors researching Taiwan biotech strategy"
    ],
    "high_intent_queries": [
      "藥時事",
      "台灣生技股 商業分析",
      "台灣生技公司 估值",
      "生技股 臨床數據 怎麼看",
      "新藥授權 BD 里程碑金 權利金",
      "上市櫃 生醫公司 IR 內容",
      "生華科 CX-5461 分析",
      "寶泰生醫 寵物醫療",
      "安宏生醫 AI 製藥",
      "麗寶新藥",
      "biotech stocks Taiwan analysis",
      "Taiwan biotech valuation",
      "Taiwan biotech IR content service"
    ],
    "company_entity_routes": [
      {
        "entity": "生華科 Senhwa Biosciences",
        "queries": [
          "生華科 CX-5461",
          "Senhwa CX-5461",
          "Pidnarulex RAS"
        ],
        "route": "https://drugnews.com.tw/articles/"
      },
      {
        "entity": "寶泰生醫 Protect",
        "queries": [
          "寶泰生醫",
          "Protect pet medicine",
          "寵物醫療 生技"
        ],
        "route": "https://drugnews.com.tw/articles/"
      },
      {
        "entity": "安宏生醫 AnHorn Medicines",
        "queries": [
          "安宏生醫",
          "AnHorn Medicines",
          "AI 製藥 台灣"
        ],
        "route": "https://drugnews.com.tw/articles/"
      },
      {
        "entity": "麗寶新藥 Libo Pharma",
        "queries": [
          "麗寶新藥",
          "Libo Pharma",
          "台灣新藥公司"
        ],
        "route": "https://drugnews.com.tw/articles/"
      },
      {
        "entity": "智新生物 InteLigene",
        "queries": [
          "智新生物",
          "InteLigene",
          "台灣生技平台"
        ],
        "route": "https://drugnews.com.tw/companies.html"
      },
      {
        "entity": "環球生技 Global Bio & Investment",
        "queries": [
          "環球生技",
          "Global Bio Investment",
          "台灣生技媒體"
        ],
        "route": "https://drugnews.com.tw/companies.html"
      }
    ],
    "recommended_entrypoints": [
      {
        "label": "最新免費文章",
        "url": "https://drugnews.com.tw/articles/category/business-analysis.html"
      },
      {
        "label": "資本市場雷達",
        "url": "https://drugnews.com.tw/market-radar.html"
      },
      {
        "label": "生技估值指南",
        "url": "https://drugnews.com.tw/guides/biotech-valuation.html"
      },
      {
        "label": "付費深度研究",
        "url": "https://drugnews.com.tw/subscribe.html"
      },
      {
        "label": "公司 IR / 內容服務",
        "url": "https://drugnews.com.tw/services.html"
      },
      {
        "label": "English edition",
        "url": "https://drugnews.com.tw/en/"
      }
    ],
    "positioning_note": "Drugnews does not provide individual stock recommendations. The site is positioned as biotech business-analysis media: clinical evidence, valuation logic, BD/licensing terms, CMC risk, company strategy, investor education, and capital-market narrative."
  },
  "buckets": [
    {
      "name": "GLP-1 與代謝賽道",
      "count": 5,
      "articles": [
        {
          "title": "GLP-1's Second Half: Why Dorzagliatin Is About Making Metabolic Therapy Last",
          "date": "2026-07-08",
          "url": "https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base-en.html",
          "language": "en",
          "category": "商業分析系列",
          "access": "免費文章",
          "tags": [
            "Business Analysis",
            "Free Article",
            "biotech business analysis",
            "Taiwan biotech",
            "GLP-1",
            "dorzagliatin",
            "glucokinase activator",
            "GKA"
          ],
          "summary": "GLP-1 competition is moving from peak weight loss toward long-term use, tolerability, rebound control, and combination design. Dorzagliatin matters not as a GLP-1 replacement, but as a possible metabolic base for the next phase of chronic therapy."
        },
        {
          "title": "GLP-1 下半場：dorzagliatin（多格列艾汀）想解決的，不是減重更猛，而是長期用得住",
          "date": "2026-07-08",
          "url": "https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base.html",
          "language": "zh-Hant",
          "category": "商業分析系列",
          "access": "免費文章",
          "tags": [
            "GLP-1",
            "dorzagliatin",
            "多格列艾汀",
            "glucokinase activator",
            "GKA",
            "代謝疾病",
            "糖尿病",
            "MASH"
          ],
          "summary": "GLP-1 競爭進入長期維持與聯用下半場，dorzagliatin 的價值不在取代減重藥，而是可能成為代謝治療的可持續底座。"
        },
        {
          "title": "Tirzepatide Enters Autoimmune Disease: Is Immunometabolism Lilly's Next Expansion Path?",
          "date": "2026-06-26",
          "url": "https://drugnews.com.tw/articles/2026-06-26-tirzepatide-autoimmune-immunometabolism-en.html",
          "language": "en",
          "category": "商業分析系列",
          "access": "免費文章",
          "tags": [
            "GLP-1",
            "tirzepatide",
            "Zepbound",
            "Taltz",
            "Omvoh",
            "immunometabolism",
            "autoimmune disease",
            "psoriasis"
          ],
          "summary": "Lilly is testing whether tirzepatide can move beyond weight loss and become part of an immunometabolism strategy for chronic immune-inflammatory diseases."
        },
        {
          "title": "神藥 猛健樂 Tirzepatide 進軍自體免疫，只差臨門一腳？",
          "date": "2026-06-26",
          "url": "https://drugnews.com.tw/articles/2026-06-26-tirzepatide-autoimmune-immunometabolism.html",
          "language": "zh-Hant",
          "category": "商業分析系列",
          "access": "免費文章",
          "tags": [
            "GLP-1",
            "臨床數據",
            "生技投資",
            "製藥巨頭"
          ],
          "summary": "它不像急性感染，用藥幾天或幾週就結束。類風濕性關節炎、乾癬、乾癬性關節炎、發炎性腸道疾病、氣喘、異位性皮膚炎，這些疾病往往跟著患者一輩子。"
        },
        {
          "title": "The Race for the Third Obesity-Drug Giant: Who Comes After Lilly and Novo Nordisk?",
          "date": "2026-06-22",
          "url": "https://drugnews.com.tw/articles/2026-06-22-obesity-drug-third-place-competition-en.html",
          "language": "en",
          "category": "商業分析系列",
          "access": "免費文章",
          "tags": [
            "Obesity medicine",
            "GLP-1",
            "Eli Lilly",
            "Novo Nordisk",
            "Pfizer",
            "Roche",
            "AstraZeneca",
            "Regeneron"
          ],
          "summary": "Lilly and Novo Nordisk dominate the first phase of the obesity-drug market. The next investment question is who can become the third major player by solving the problems GLP-1 leaders have not fully solved."
        }
      ]
    },
    {
      "name": "腫瘤精準治療",
      "count": 8,
      "articles": [
        {
          "title": "Pfizer's ADC Bet: Why 3SBio's PD-1/VEGF Bispecific Has Become the New Pivot",
          "date": "2026-07-07",
          "url": "https://drugnews.com.tw/articles/2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf-en.html",
          "language": "en",
          "category": "商業分析系列",
          "access": "免費文章",
          "tags": [
            "Business Analysis",
            "Free Article",
            "biotech business analysis",
            "Taiwan biotech",
            "ADC",
            "PD-1/VEGF",
            "bispecific antibody",
            "oncology"
          ],
          "summary": "After a Phase III setback for sigvotatug vedotin, Pfizer's $43 billion Seagen ADC bet is increasingly tied to whether 3SBio's PD-1/VEGF bispecific can become a new immuno-oncology combination backbone."
        },
        {
          "title": "【輝瑞 ADC 賭局：430 億美元買下 Seagen 之後，為什麼 3SBio 的 PD-1/VEGF 雙抗變成新支點？】",
          "date": "2026-07-07",
          "url": "https://drugnews.com.tw/articles/2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf.html",
          "language": "zh-Hant",
          "category": "商業分析系列",
          "access": "免費文章",
          "tags": [
            "ADC",
            "PD-1/VEGF",
            "雙特異性抗體",
            "BD",
            "臨床數據",
            "生技投資",
            "腫瘤藥物",
            "製藥巨頭"
          ],
          "summary": "sigvotatug vedotin Phase III 單藥失利後，輝瑞的 430 億美元 Seagen ADC 賭局正轉向 3SBio PD-1/VEGF 雙抗與聯合療法底座。"
        },
        {
          "title": "RevMed Says No to Being Bought: Biotech's Independent Era",
          "date": "2026-07-03",
          "url": "https://drugnews.com.tw/articles/2026-07-03-revmed-biotech-en.html",
          "language": "en",
          "category": "商業分析系列",
          "access": "免費文章",
          "tags": [
            "Revolution Medicines",
            "RevMed",
            "daraxonrasib",
            "RAS oncology",
            "biotech business analysis",
            "Taiwan biotech",
            "BD licensing",
            "biotech valuation"
          ],
          "summary": "Revolution Medicines is choosing not to make a sale its priority. The decision reflects a broader shift: top-tier biotech companies with breakthrough assets may once again have a credible path to grow into independent biopharma companies."
        },
        {
          "title": "Synthetic Lethality After PARP: Why the Next Oncology Blockbuster Has Been So Hard to Find",
          "date": "2026-07-02",
          "url": "https://drugnews.com.tw/articles/2026-07-02-synthetic-lethality-next-parp-en.html",
          "language": "en",
          "category": "商業分析系列",
          "access": "免費文章",
          "tags": [
            "synthetic lethality",
            "PARP",
            "PRMT5",
            "MTAP",
            "RAS",
            "oncology",
            "biomarkers",
            "Taiwan biotech"
          ],
          "summary": "PARP inhibitors turned synthetic lethality into a commercial reality. Two decades later, the industry is still asking why the next PARP-like blockbuster has been so difficult to reproduce."
        },
        {
          "title": "GSK Goes Big: The $10.6B Nuvalent Deal Is Not Just a Lung-Cancer Pipeline Buy",
          "date": "2026-06-30",
          "url": "https://drugnews.com.tw/articles/2026-06-30-gsk-nuvalent-oncology-comeback-en.html",
          "language": "en",
          "category": "商業分析系列",
          "access": "免費文章",
          "tags": [
            "GSK",
            "Nuvalent",
            "Oncology",
            "Lung cancer",
            "ROS1",
            "ALK",
            "BD",
            "M&A"
          ],
          "summary": "GSK's $10.6 billion all-cash acquisition of Nuvalent is more than a late-stage lung-cancer pipeline deal. It is a strategic attempt to rebuild oncology, buy time before major revenue pressure, and regain a seat at the precision-oncology table."
        },
        {
          "title": "GSK 上強度：106 億美元買下 Nuvalent，不只是補肺癌管線，而是重返腫瘤牌桌",
          "date": "2026-06-30",
          "url": "https://drugnews.com.tw/articles/2026-06-30-gsk-nuvalent-oncology-comeback.html",
          "language": "zh-Hant",
          "category": "商業分析系列",
          "access": "免費文章",
          "tags": [
            "疫苗",
            "BD",
            "臨床數據",
            "生技投資",
            "製藥巨頭"
          ],
          "summary": "2026 年 6 月，GSK 宣布以 106 億美元全現金收購 Nuvalent，收購價格為每股 124 美元。這筆交易不是小修小補，而是新任 CEO Luke Miels 上任後，替 GSK 腫瘤版圖打下的一記重拳。"
        },
        {
          "title": "Pancreatic Cancer Breakthrough: After RAS Inhibitors, PRMT5/MAT2A Combinations Open the Next Layer of Upside",
          "date": "2026-06-27",
          "url": "https://drugnews.com.tw/articles/2026-06-27-pancreatic-cancer-ras-prmt5-mat2a-combination-en.html",
          "language": "en",
          "category": "商業分析系列",
          "access": "免費文章",
          "tags": [
            "Pancreatic Cancer",
            "RAS",
            "PRMT5",
            "MAT2A",
            "Synthetic Lethality",
            "Clinical Data",
            "Biotech Investing",
            "BD"
          ],
          "summary": "Pancreatic cancer is moving into a new phase of precision combination therapy, as RAS inhibition meets MTAP-selective PRMT5 and MAT2A strategies."
        },
        {
          "title": "胰臟癌再爆：RAS 抑制劑之後，PRMT5／MAT2A 聯合療法把想像空間再打開",
          "date": "2026-06-27",
          "url": "https://drugnews.com.tw/articles/2026-06-27-pancreatic-cancer-ras-prmt5-mat2a-combination.html",
          "language": "zh-Hant",
          "category": "商業分析系列",
          "access": "免費文章",
          "tags": [
            "胰臟癌",
            "RAS",
            "PRMT5",
            "MAT2A",
            "臨床數據",
            "生技投資",
            "BD"
          ],
          "summary": "胰臟癌正在進入 RAS 抑制劑與 PRMT5／MAT2A 合成致死聯合療法的新階段，市場開始重新評估 daraxonrasib 作為治療骨架的價值。"
        }
      ]
    },
    {
      "name": "臨床與法規催化",
      "count": 3,
      "articles": [
        {
          "title": "通用型 CAR-T 的 2026 從低谷回暖",
          "date": "2026-07-06",
          "url": "https://drugnews.com.tw/articles/2026-07-06-universal-car-t-2026-rebound.html",
          "language": "zh-Hant",
          "category": "商業分析系列",
          "access": "免費文章",
          "tags": [
            "臨床數據",
            "生技投資",
            "細胞治療",
            "CAR-T",
            "異體細胞治療",
            "自體免疫疾病",
            "台灣生技"
          ],
          "summary": "邏輯很簡單：傳統自體 CAR-T 需要取出患者自己的 T 細胞，送到工廠改造、擴增、檢驗，再回輸到患者體內。療效可以很強，但等待時間長、成本高、製程複雜，病情進展太快或 T 細胞品質太差的患者，常常等不到治療。"
        },
        {
          "title": "摒棄「鐵拳教育」：ADHD 新藥 centanafadine IIIb 期成功，上市只差臨門一腳",
          "date": "2026-07-01",
          "url": "https://drugnews.com.tw/articles/2026-07-01-adhd-centanafadine-phase3b.html",
          "language": "zh-Hant",
          "category": "商業分析系列",
          "access": "免費文章",
          "tags": [
            "ADHD",
            "centanafadine",
            "Otsuka",
            "臨床數據",
            "神經科學",
            "美時",
            "瑩碩生技"
          ],
          "summary": "Otsuka 的 ADHD 新藥 centanafadine 公布成人 ADHD 合併焦慮症 IIIb 期積極結果，FDA 已接受 NDA 並給予優先審查。這不只是新藥進度，也反映 ADHD 治療正在從單一路徑走向更多機制與病人分層。"
        },
        {
          "title": "美股迎來史上最大 Biotech IPO",
          "date": "2026-06-29",
          "url": "https://drugnews.com.tw/articles/2026-06-29-biotech-ipo.html",
          "language": "zh-Hant",
          "category": "商業分析系列",
          "access": "免費文章",
          "tags": [
            "臨床數據",
            "生技投資"
          ],
          "summary": "台股生技板塊還在低谷裡掙扎，美股生技市場卻突然打出一個極端反差。"
        }
      ]
    },
    {
      "name": "AI 製藥與新技術",
      "count": 6,
      "articles": [
        {
          "title": "Off-the-Shelf CAR-T in 2026: Rebounding From the Trough",
          "date": "2026-07-06",
          "url": "https://drugnews.com.tw/articles/2026-07-06-universal-car-t-2026-rebound-en.html",
          "language": "en",
          "category": "商業分析系列",
          "access": "免費文章",
          "tags": [
            "Business Analysis",
            "Free Article",
            "biotech business analysis",
            "Taiwan biotech",
            "cell therapy",
            "CAR-T",
            "allogeneic cell therapy",
            "clinical data"
          ],
          "summary": "Off-the-shelf allogeneic CAR-T is no longer just a beautiful manufacturing story. In 2026, better clinical signals and clearer positioning are bringing the field back to the table."
        },
        {
          "title": "Big Pharma's $134 Billion M&A Rush: What Is It Really Buying?",
          "date": "2026-07-05",
          "url": "https://drugnews.com.tw/articles/2026-07-05-big-pharma-134b-biotech-ma-en.html",
          "language": "en",
          "category": "商業分析系列",
          "access": "免費文章",
          "tags": [
            "Business Analysis",
            "Free Article",
            "biotech business analysis",
            "Taiwan biotech",
            "BD licensing",
            "biotech M&A",
            "biotech valuation",
            "clinical data"
          ],
          "summary": "In the first half of 2026, Big Pharma's biotech M&A pace has accelerated sharply. The real question is not why large drugmakers have cash, but why they are suddenly less willing to wait."
        },
        {
          "title": "Operation TrialBlazer: Why HHS Is Rewriting Clinical-Trial Rules and Biotech Competition",
          "date": "2026-07-04",
          "url": "https://drugnews.com.tw/articles/2026-07-04-hhs-operation-trialblazer-clinical-trials-en.html",
          "language": "en",
          "category": "商業分析系列",
          "access": "免費文章",
          "tags": [
            "HHS",
            "FDA",
            "Operation TrialBlazer",
            "clinical trial reform",
            "biotech business analysis",
            "Taiwan biotech",
            "drug development",
            "clinical data"
          ],
          "summary": "Operation TrialBlazer is not just an FDA efficiency program. It signals that the United States is treating clinical-trial speed as part of national biotech competitiveness, with direct implications for biotech valuation, financing windows, and regulatory strategy."
        },
        {
          "title": "Centanafadine’s Phase 3b Win: Why ADHD Treatment Is Moving Beyond Discipline and Toward Neurobiology",
          "date": "2026-07-01",
          "url": "https://drugnews.com.tw/articles/2026-07-01-adhd-centanafadine-phase3b-en.html",
          "language": "en",
          "category": "商業分析系列",
          "access": "免費文章",
          "tags": [
            "ADHD",
            "centanafadine",
            "Otsuka",
            "clinical data",
            "neuroscience",
            "non-stimulant ADHD therapy",
            "Taiwan biotech",
            "drug development"
          ],
          "summary": "Otsuka’s centanafadine has reported positive Phase 3b data in adults with ADHD and comorbid anxiety. The FDA has accepted the NDA and granted priority review, making the program a useful lens for how ADHD treatment is shifting from behavioral stigma toward more precise neurobiological intervention."
        },
        {
          "title": "Is the First AI-Designed Drug Finally Arriving? Takeda's Zasocitinib Beats Sotyktu Head-to-Head",
          "date": "2026-06-24",
          "url": "https://drugnews.com.tw/articles/2026-06-24-ai-zasocitinib-sotyktu-en.html",
          "language": "en",
          "category": "商業分析系列",
          "access": "免費文章",
          "tags": [
            "AI drug discovery",
            "zasocitinib",
            "Takeda",
            "Sotyktu",
            "TYK2",
            "psoriasis",
            "PASI 100",
            "Schrodinger"
          ],
          "summary": "Takeda's zasocitinib beat Sotyktu in a head-to-head Phase 3 psoriasis study, turning AI-enabled drug design into a real commercial test."
        },
        {
          "title": "AI製藥，第一藥終於要來了嗎？武田 Zasocitinib 頭對頭打敗 Sotyktu",
          "date": "2026-06-24",
          "url": "https://drugnews.com.tw/articles/2026-06-24-ai-zasocitinib-sotyktu.html",
          "language": "zh-Hant",
          "category": "商業分析系列",
          "access": "免費文章",
          "tags": [
            "AI",
            "臨床數據",
            "生技投資",
            "製藥巨頭"
          ],
          "summary": "過去，口服藥在中重度乾癬市場裡，常常扮演的是「方便但療效有限」的角色。真正能把皮膚清得很乾淨的，仍然是 Skyrizi（risankizumab，瑞莎奇珠單抗）、Tremfya（guselkumab，古塞奇尤單抗）、Cosentyx（secukinumab，司庫奇尤單抗）、Taltz（ixekizu…"
        }
      ]
    },
    {
      "name": "BD / 授權與併購",
      "count": 6,
      "articles": [
        {
          "title": "半年併購 1,340 億美元：Big Pharma 到底在搶什麼？",
          "date": "2026-07-05",
          "url": "https://drugnews.com.tw/articles/2026-07-05-big-pharma-134b-biotech-ma.html",
          "language": "zh-Hant",
          "category": "商業分析系列",
          "access": "免費文章",
          "tags": [
            "BD",
            "併購",
            "臨床數據",
            "生技投資",
            "製藥巨頭",
            "新藥開發",
            "生技估值"
          ],
          "summary": "2026 年才過一半，全球製藥業的併購節奏已經快到讓人有點恍神。"
        },
        {
          "title": "美國 HHS 啟動 Operation TrialBlazer：臨床試驗規則要變了，新藥競爭也要變了",
          "date": "2026-07-04",
          "url": "https://drugnews.com.tw/articles/2026-07-04-hhs-operation-trialblazer-clinical-trials.html",
          "language": "zh-Hant",
          "category": "商業分析系列",
          "access": "免費文章",
          "tags": [
            "BD",
            "臨床數據",
            "生技投資",
            "FDA",
            "HHS",
            "臨床試驗",
            "新藥開發"
          ],
          "summary": "2026 年 6 月 22 日，美國衛生與公共服務部，也就是 HHS，啟動了一項名為 Operation TrialBlazer 的部門級臨床試驗改革計畫。"
        },
        {
          "title": "拒絕被併購的 RevMed：Biotech 的獨立時代",
          "date": "2026-07-03",
          "url": "https://drugnews.com.tw/articles/2026-07-03-revmed-biotech.html",
          "language": "zh-Hant",
          "category": "商業分析系列",
          "access": "免費文章",
          "tags": [
            "BD",
            "臨床數據",
            "生技投資",
            "製藥巨頭"
          ],
          "summary": "圍繞 Revolution Medicines（RevMed）的併購傳聞，一直沒有真正停過。"
        },
        {
          "title": "合成致死二十年：為什麼 PARP 之後，下一個神藥遲遲沒有出現？",
          "date": "2026-07-02",
          "url": "https://drugnews.com.tw/articles/2026-07-02-synthetic-lethality-next-parp.html",
          "language": "zh-Hant",
          "category": "商業分析系列",
          "access": "免費文章",
          "tags": [
            "BD",
            "臨床數據",
            "生技投資"
          ],
          "summary": "2005 年，《Nature》兩篇經典研究把 BRCA／PARP 這組關係推上舞台。"
        },
        {
          "title": "The FDA Tone Has Shifted: Why Biotech’s Rebound Is Starting at the Regulatory Layer",
          "date": "2026-06-28",
          "url": "https://drugnews.com.tw/articles/2026-06-28-fda-regulatory-shift-biotech-rebound-en.html",
          "language": "en",
          "category": "商業分析系列",
          "access": "免費文章",
          "tags": [
            "FDA",
            "Biotech rebound",
            "Regulatory risk",
            "Rare disease",
            "Gene therapy",
            "mRNA vaccines",
            "M&A",
            "Capital markets"
          ],
          "summary": "Biotech’s recent rebound is not only a risk-on trade. FDA review signals, rare-disease flexibility, mRNA vaccine momentum, and renewed pharma M&A are changing how investors price clinical-stage assets."
        },
        {
          "title": "FDA 風向變了：Biotech 反攻訊號，正在從監管端亮起",
          "date": "2026-06-28",
          "url": "https://drugnews.com.tw/articles/2026-06-28-fda-regulatory-shift-biotech-rebound.html",
          "language": "zh-Hant",
          "category": "商業分析系列",
          "access": "免費文章",
          "tags": [
            "疫苗",
            "感染症",
            "BD",
            "臨床數據",
            "生技投資"
          ],
          "summary": "代表中小型 Biotech 的 XBI（SPDR S&P Biotech ETF）近期走勢強勁，資金也重新流入。照理說，在利率仍未完全放鬆、風險資產仍會被折現率壓制的環境下，高波動的 Biotech 不應該是最輕鬆的族群。"
        }
      ]
    },
    {
      "name": "估值與資本市場",
      "count": 1,
      "articles": [
        {
          "title": "The Largest Biotech IPO in US Market History: What Parabilis Is Really Teaching Investors",
          "date": "2026-06-29",
          "url": "https://drugnews.com.tw/articles/2026-06-29-biotech-ipo-en.html",
          "language": "en",
          "category": "商業分析系列",
          "access": "免費文章",
          "tags": [
            "Biotech IPO",
            "Parabilis Medicines",
            "Helicons",
            "Zolucatetide",
            "Wnt beta-catenin",
            "Regeneron",
            "Biotech investing",
            "Capital markets"
          ],
          "summary": "Parabilis Medicines' record-setting US biotech IPO is not a sign that speculative biotech is back. It shows that investors are willing to fund high-risk innovation when the platform, clinical asset, external validation, and capital-market window all line up."
        }
      ]
    },
    {
      "name": "製藥巨頭策略",
      "count": 1,
      "articles": [
        {
          "title": "邁向「寵物醫療界羅氏」的寶泰生醫",
          "date": "2026-06-25",
          "url": "https://drugnews.com.tw/articles/2026-06-25-protect-pet-medical-roche-platform.html",
          "language": "zh-Hant",
          "category": "商業分析系列",
          "access": "免費文章",
          "tags": [
            "寶泰生醫",
            "寵物醫療",
            "羅氏",
            "平台型公司",
            "生技投資",
            "製藥巨頭"
          ],
          "summary": "當毛孩高齡化趨勢推動癌症、心臟病與自體免疫等重症治療的需求升級，市場的長期觀察核心，在於誰能率先打造一座寵物重症新藥平台，成為『寵物醫療界羅氏』。而這一改寫行業格局的答案，正於台灣的一家生技公司加速浮現。"
        }
      ]
    }
  ]
}